ProCE Banner Activity

Identification and Management of Adverse Events With TROP-2–Targeted ADCs

Slideset

Matthew Gubens, MD, MS, FASCO, reviews key toxicities with TROP-2–targeted ADCs under investigation for the treatment of advanced NSCLC and recommended management.

Released: April 04, 2024

Expiration: April 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.